Document › Details

Adaptimmune Therapeutics plc. (8/1/19). "Press Release: Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update". Philadeliphia, PA & Oxfordshire.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 Alpine Immune Sciences Inc. (Nasdaq: ALPN)
Products Product ADP-A2M4 SPEAR T-cell therapy
  Product 2 T cell therapy
Index term Index term Adaptimmune–Alpine Immune Sciences: cell therapy technology, 201905– collab + license to incorporte SIP + TIP technology into SPEAR T-cell therapies
Persons Person Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
  Person 2 Rawcliffe, Adrian (Ad) (Adaptimmune 201909– CEO joined 201503 as CFO before GSK)

Record changed: 2019-08-07


Picture [LSUK] – The Business Web Portal 650x99px

More documents for Adaptimmune (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top